End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.9 CNY | +0.23% | 0.00% | -24.21% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.21% | 2.66B | B- | ||
+12.92% | 4.95B | B- | ||
-32.29% | 3.6B | C+ | ||
-4.28% | 3.03B | C | ||
-8.82% | 2.34B | - | D+ | |
+39.33% | 1.85B | - | ||
+40.81% | 1.45B | - | ||
-14.27% | 1.41B | - | - | |
+41.90% | 1.38B | - | ||
-25.47% | 1.31B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600535 Stock
- Ratings Tasly Pharmaceutical Group Co., Ltd